Published in Ann Rheum Dis on April 13, 2005
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis (2006) 1.93
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis (2007) 1.68
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther (2015) 1.61
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum (2012) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther (2010) 1.55
The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther (2014) 1.42
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer (2010) 1.25
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res (2009) 1.25
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis (2006) 1.24
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) (2013) 1.21
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis (2008) 1.12
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis (2014) 1.10
Treating rheumatic patients with a malignancy. Arthritis Res Ther (2011) 1.03
Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J (2010) 1.03
The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther (2010) 1.02
The Development of Novel Therapies for Rheumatoid Arthritis. Expert Opin Ther Pat (2008) 0.99
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy (2013) 0.99
Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther (2013) 0.99
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer (2011) 0.95
Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95
Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum (2013) 0.92
Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol (2010) 0.90
Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database. Int J Rheumatol (2009) 0.90
Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go? Arthritis Res Ther (2007) 0.86
Adalimumab in the treatment of arthritis. Ther Clin Risk Manag (2007) 0.86
No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. Rheumatol Int (2014) 0.83
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis (2015) 0.82
Co-morbidity in patients with early rheumatoid arthritis - inflammation matters. Arthritis Res Ther (2016) 0.82
Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag (2006) 0.80
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Personal and family medical history correlates of rheumatoid arthritis. Ann Epidemiol (2008) 0.79
Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence? Clin Rheumatol (2012) 0.79
[Medication treatment of rheumatoid arthritis with a history of malignancy : Epidemiological data]. Z Rheumatol (2016) 0.78
[Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients]. Z Rheumatol (2009) 0.78
The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford) (2016) 0.77
Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord (2012) 0.77
Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol (2006) 0.76
Conditional Disease Development extracted from Longitudinal Health Care Cohort Data using Layered Network Construction. Sci Rep (2016) 0.76
Melanoma and rheumatoid arthritis (brief report). Clin Rheumatol (2012) 0.76
Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Musculoskelet Disord (2015) 0.76
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. Drug Healthc Patient Saf (2010) 0.76
Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol (2010) 0.76
Rheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome. Am J Case Rep (2015) 0.75
TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol (2014) 0.75
Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)? Ecancermedicalscience (2016) 0.75
Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report. BMC Res Notes (2014) 0.75
Online training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based survey. PLoS One (2015) 0.75
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open (2016) 0.75
Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor. Medicine (Baltimore) (2017) 0.75
A case of cervical spine meningioma following etanercept use in a patient with RA. Nat Rev Rheumatol (2009) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Two cases of renal cell cancer during immunobiologic therapy for psoriasis. An Bras Dermatol (2014) 0.75
Breast cancer risk in rheumatoid arthritis: an update meta-analysis. Biomed Res Int (2014) 0.75
Epidemiology research in rheumatology-progress and pitfalls. Nat Rev Rheumatol (2015) 0.75
Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol (2015) 0.75
Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma-challenges in management. Int J Colorectal Dis (2015) 0.75
[Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer]. Z Rheumatol (2016) 0.75
[Malignancies of the skin and immunomodulatory antirheumatic therapy]. Z Rheumatol (2016) 0.75
The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Clin Rheumatol (2017) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol (1984) 5.36
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis (2003) 4.36
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Risk of malignancy among patients with rheumatic conditions. Int J Cancer (2000) 2.70
Rheumatoid arthritis and cancer risk. Eur J Cancer (1996) 2.44
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer (2003) 2.43
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25
The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2 (1980) 2.07
Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum (1997) 1.69
Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis (1980) 1.57
Neoplasms of the immune system in rheumatoid arthritis. Am J Med (1985) 1.52
Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol (1995) 1.37
Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis (2002) 1.32
Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum (2004) 1.27
Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control (1997) 1.18
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14
No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum (1998) 1.03
Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold. Scand J Rheumatol (1995) 0.97
Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. Ann Rheum Dis (1982) 0.95
Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am (2004) 0.91
Rating systems in the evaluation of knee ligament injuries. Clin Orthop Relat Res (1985) 9.85
Evaluation of knee ligament surgery results with special emphasis on use of a scoring scale. Am J Sports Med (1982) 5.94
Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ (1994) 5.22
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis (2003) 4.36
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry (2001) 4.15
Epidermal Langerhans cells express Ia antigens. Nature (1977) 3.51
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis (2003) 3.43
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) (2005) 3.42
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol (1999) 3.15
Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage (2006) 3.10
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis (2002) 3.10
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res (2000) 2.88
Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods (1988) 2.84
Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med (2013) 2.74
Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ (1994) 2.67
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis (2005) 2.62
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61
Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum (1986) 2.56
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ (1998) 2.51
IQ and risk for schizophrenia: a population-based cohort study. Psychol Med (1997) 2.47
Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. J Rheumatol (2001) 2.45
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med (2010) 2.30
Injuries in runners. Am J Sports Med (1987) 2.29
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25
Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis (2004) 2.25
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
Isolation and characterization of dermatan sulphate proteoglycans from bovine sclera. Biochem J (1981) 2.23
The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol (1999) 2.20
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17
Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis (2002) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Appearance of anti-HLA-DR-reactive cells in normal and rheumatoid synovial tissue. Scand J Immunol (1981) 2.02
No survival benefit from early-start dialysis in a population-based, inception cohort study of Swedish patients with chronic kidney disease. J Intern Med (2010) 2.01
Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci U S A (1982) 1.99
T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol (1985) 1.96
Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2005) 1.96
Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis (1997) 1.95
Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum (1989) 1.95
Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis (2006) 1.93
Hormonal regulation of the expression of Ia antigens on mammary gland epithelium. Eur J Immunol (1980) 1.90
Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum (1986) 1.90
Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol (1985) 1.89
The core proteins of large and small interstitial proteoglycans from various connective tissues form distinct subgroups. Biochem J (1985) 1.89
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol (1996) 1.78
Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum (1983) 1.78
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol (2007) 1.77
Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest (1995) 1.77
Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ (2000) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
Occurrence of Ia antigens on tissues on non-lymphoid origin. Nature (1978) 1.76
Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol (1994) 1.74
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (2001) 1.72
The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol (2011) 1.71
Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis (2008) 1.71